By successfully turning the “cold” tumor into “hot” – transforming the tumor microenvironment from having low immune activity to an active immune environment – ERNA-101 may not only lead to improved ...

Ovarian cancer, often called the silent killer, presents one of the most serious health threats women face globally. Its ...

ERNA-101 is a cell therapy that utilizes induced pluripotent stem cells (iPSCs ... researchers developed an ovarian tumor model by injecting ID8 cells intraperitoneally into mice.

Eterna Therapeutics, Inc. (ERNA) announced Tuesday positive results from a preclinical study on the company's lead cell therapy ...

showcased a significant increase in T cell infiltration, tumor size reduction, and extended survival in an ovarian cancer mouse model. The therapy, ERNA-101, uses induced pluripotent stem cells to ...

IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce ...

small cell lung cancer and other indications. The Phase III clinical study (FLAMES Study) of Senaparib for advanced ovarian cancer maintenance treatment following first-line therapy met primary ...

Every 40 seconds, someone in the United States has a stroke. For survivors of the most common type of stroke, called an ...

Scientists have developed a new strategy to enhance pharmaceutical production in Chinese hamster ovary (CHO) cells, which are commonly used to manufacture protein-based drugs for treating cancer, ...

The tests can work using any bodily fluid that might contain cell-free ... both for ovarian cancer and for other solid tumours. In fact, these tests could have a role at multiple points in the patient ...